Dyne Therapeutics Inc
Company Profile
Business description
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Contact
1560 Trapelo Road
WalthamMA02451
USAT: +1 781 786-8230
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
258
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,897.00 | 59.20 | -0.66% |
| CAC 40 | 8,081.43 | 41.98 | -0.52% |
| DAX 40 | 25,266.53 | 144.10 | -0.57% |
| Dow JONES (US) | 51,349.98 | 161.61 | -0.31% |
| FTSE 100 | 10,679.99 | 25.27 | -0.24% |
| HKSE | 24,761.13 | 72.99 | -0.29% |
| NASDAQ | 26,939.37 | 3.34 | 0.01% |
| Nikkei 225 | 65,513.99 | 495.04 | 0.76% |
| NZX 50 Index | 13,768.61 | 56.22 | -0.41% |
| S&P 500 | 7,704.13 | 1.90 | -0.02% |
| S&P/ASX 200 | 8,702.00 | 63.30 | -0.72% |
| SSE Composite Index | 3,888.37 | 48.15 | -1.22% |